The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer

Expert Opinion on Investigational Drugs

Volumn 25, Issue 4, 2016, Pages 385-392

  Passiglia, Francesco ^a   Caparica, Rafael ^b   Giovannetti, Elisa ^c   Giallombardo, Marco ^a,d   Listi, Angela ^a   Diana, Patrizia ^a   Cirrincione, Girolamo ^a   Caglevic, Christian ^e   Raez, Luis E ^f   Russo, Antonio ^a   Rolfo, Christian ^d  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e Instituto Oncológico Fundación Arturo López Pérez   (Chile)

^f FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

lung cancer; NTRK1 2 3; NTRKinhibitors; targeted therapy; TrkA B C

Indexed keywords

ENTRECTINIB; LOXO 101; NEUROTROPHIC TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ANTINEOPLASTIC ACTIVITY; CANCER RESEARCH; DRUG POTENCY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; LUNG NEOPLASMS;

ANIMALS; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84959051321     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2016.1152261     Document Type: Review

References (49)

1. Bronte G, Rolfo C, Giovannetti E, et al. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Crit Rev Oncol Hematol. 2014;89:300-313.
2. Rolfo C, Passiglia F, Castiglia M, et al. ALK and crizotinib: after the honeymoon what else? Resistance mechanisms and new therapies to overcome it. Transl Lung Cancer Res. 2014;3:250-261.
3. Passiglia F, Bronte G, Castiglia M, et al. Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls? Expert Opin Biol Ther. 2015;15(11):1553-1566.
4. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311:1998-2006.
5. Sholl LM, Aisner DL, Varella-Garcia M, et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience. J Thorac Oncol. 2015;10:768-777.
6. Vaishnavi A, Cappelletti M, Le AT, et al. Oncogenic and drugsensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013;19:1469-1472.
7. Doebele RC, Davis LE, Vaishnavi A, et al. An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discov. 2015;5:1049-1057.
8. Brodeur GM, Minturn JE, Ho R, et al. Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res. 2009;15:3244-3250.
9. Kaplan DR, Martin-Zanca D, Parada LF. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature. 1991;350:158-160.
10. Klein R, Jing SQ, Nanduri V, et al. The trk proto-oncogene encodes a receptor for nerve growth factor. Cell. 1991;65:189-197.
11. Loeb DM, Stephens RM, Copeland T, et al. A Trk nerve growth factor (NGF) receptor point mutation affecting interaction with phospholipase C-gamma 1 abolishes NGF-promoted peripherin induction but not neurite outgrowth. J Biol Chem. 1994;269:8901-8910.
12. Siniscalco D, Giordano C, Rossi F, et al. Role of neurotrophins in neuropathic pain. Curr Neuropharmacol. 2011;9:523-529.
13. Greco A, Miranda C, Pierotti MA. Rearrangements of NTRK1 gene in papillary thyroid carcinoma. Mol Cell Endocrinol. 2010;321(1):44-49.
14. Pierotti MA, Vigneri P, Bongarzone I. Rearrangements of RET and NTRK1 tyrosine kinase receptors in papillary thyroid carcinomas. Recent Results Cancer Res. 1998;154:237-247.
15. Greco A, Miranda C, Pagliardini S, et al. Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes. Genes Chromosomes Cancer. 1997;19(2):112-123.
16. Ross JS, Wang K, Gay L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014;19(3):235-242.
17. Zheng Z, Liebers M, Zhelyazkova B, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 2014;20 (12):1479-1484.
18. Wiesner T, He J, Yelensky R, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun. 2014;5:3116.
19. Ardini E, Bosotti R, Borgia AL, et al. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol. 2014;8 (8):1495-1507.
20. Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014;46(5):444-450.
21. Stransky N, Cerami E, Schalm S, et al. The landscape of kinase fusions in cancer. Nat Commun. 2014;5:4846.
22. Jones DT, Hutter B, Jäger N, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013;45 (8):927-932.
23. Leeman-Neill RJ, Kelly LM, Liu P, et al. ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer. Cancer. 2014;120(6):799-807.
24. Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2(5):367-376.
25. Bishop JA, Yonescu R, Batista D, et al. Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma. Hum Pathol. 2013;44(10):1982-1988.
26. Knezevich SR, McFadden DE, Tao W, et al. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998;18 (2):184-187.
27. Harada T, Yatabe Y, Takeshita M, et al. Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clin Cancer Res. 2011;17:2638-2645.
28. Sinkevicius KW, Kriegel C, Bellaria KJ, et al. Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis. Proc Natl Acad Sci U S A. 2014;111:10299-10304.
29. Okamura K, Harada T, Wang S, et al. Expression of TrkB and BDNF is associated with poor prognosis in non-small cell lung cancer. Lung Cancer. 2012;78:100-106.
30. Varella-Garcia M, Kako S, Nguyen C, et al. FISHing TRK activation by gene rearrangements in non small cell lung cancer. J Thorac Oncol. 2015;10(9). http://journals.lww.com/jto/toc/2015/09001.
31. Tatematsu T, Sasaki H, Shimizu S, et al. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro. Mol Clin Oncol. 2014;2:725-730.
32. Farago AF, Le LP, Zheng Z, et al. Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer. J Thorac Oncol. 2015;10:1670-1674.
33. Arevalo JC, Conde B, Hempstead BL, et al. TrkA immunoglobulinlike ligand binding domains inhibit spontaneous activation of the receptor. Mol Cell Biol. 2000;20:5908-5916.
34. Nanda N, Fennel T, Low JA. Identification of tropomyosin kinase receptor (TRK) mutations in cancer. J Clin Oncol. 2015;33(suppl; abstr 1553).
35. Odate S, Nakamura K, Onishi H, et al. TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma. Lung Cancer. 2013;79:205-214.
36. Odate S, Onishi H, Nakamura K, et al. Tropomyosin-related kinase B inhibitor has potential for tumor regression and relapse prevention in pulmonary large cell neuroendocrine carcinoma. Anticancer Res. 2013;33:3699-3703.
37. Anderson D, Ciomei M, Banfi P, et al. Inhibition of Trk-driven tumors by the pan-Trk inhibitor RXDX-101. Ejc. 2014;50 (Supplement 6):101.
38. Ardini E, Menichincheri M, De Ponti C, et al. Characterization of NMS-E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK-dependent lymphoma and non-small cell lung cancer models. Mol Cancer Ther. 2009;8(12 suppl):abstr A243.
39. Ardini E, Menichincheri M, Banfi P, et al. The ALK inhibitor NMSE628 also potentially inhibits ROS1 and induces tumor regression in ROS1-driven models. Washington (DC): AACR; 2013. Philadelphia. Abstract n. 2092
40. Smeyne RJ, Klein R, Schnapp A, et al. Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. Nature. 1994;368:246-249.
41. Longo FM, Massa SM. Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease. Nat Rev Drug Discov. 2013;12:507-525.
42. De Braud FG, Niger M, Damian S, et al. Alka-372-001: First-inhuman, phase I study of entrectinib-an oral pan-trk, ROS1, and ALK inhibitor-in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol. 2015;33 (suppl; abstr 2517).
43. Patel MR, Bauer TM, Liu SV, et al. STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol. 2015;33 (suppl; abstr 2596).
44. Burris HA, Brose MS, Shaw AT, et al. A first-in-human study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family. J Clin Oncol. 2015;33 (suppl; abstr TPS2624).
45. TRK inhibitor shows early promise. Cancer Discov. 2016;6(1):OF4.
46. Collisson EA, Campbell JD, Brooks AN, et al. comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511 (7511):543-550.
47. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13:1011-1019.
48. Kim DK, Ahn MJ, Shi Y, et al. Updated results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol. 2012;30:abstr 7533.
49. Raez LE. NTRK Family (TRK1, TRK2 and TRK3) and PTPN11: New Targets in NSCLC Therapy. J Thorac Oncol. 2015;10(9). http://jour nals.lww.com/jto/toc/2015/09001.